● Recruiting

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Condition: Clear Cell Renal Cell Carcinoma · Solid Tumors · Sponsor: Arcus Biosciences, Inc.

PhasePhase 1

Planned participants362

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab or zimberelimab and ipilimumab in participants with ccRCC in the dose expansion stage.

This description comes directly from the study's public registry record.

Talk to the study team

Medical Director · +1-510-462-3330 · ClinicalTrialInquiry@arcusbio.com

Always discuss trial participation with your own doctor first.

Locations (25)

Research Site	Birmingham, Alabama, United States	Recruiting
Research Site	San Diego, California, United States	Recruiting
Research Site	Santa Monica, California, United States	Recruiting
Research Site	Miami, Florida, United States	Recruiting
Research Site	Atlanta, Georgia, United States	Recruiting
Research Site	Louisville, Kentucky, United States	Recruiting
Research Site	New Orleans, Louisiana, United States	Recruiting
Research Site	Baltimore, Maryland, United States	Recruiting
Research Site	Boston, Massachusetts, United States	Recruiting
Research Site	Detroit, Michigan, United States	Recruiting
Research Site	Detroit, Michigan, United States	Recruiting
Research Site	Omaha, Nebraska, United States	Recruiting

+ 13 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05536141